Immunoglobulin IgG3 as a marker for protecting against...

Details Immunoglobulin IgG3 as a marker for protecting against... Immunoglobulin IgG3 as a marker for protecting against...

2007-12-11

2007-12-11

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S139100, C424S141100, C424S147100, C424S148100

Reexamination Certificate

active

10504802

ABSTRACT:
The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic tool, or as a preventive and curative medicament. The invention also relates to corresponding in vitro diagnostic methods.

REFERENCES:
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 6113902 (2000-09-01), Chermann et al.
patent: 2003/0021800 (2003-01-01), Chermann et al.
patent: 0 470 989 (1994-07-01), None
Wei, X. Antibody neutralization and escape by HIV-1. Nature vol. 422 (Mar. 20, 2003), pp. 307-312.
Buckley, R. IgG Subclass Deficiency (Dec. 1998). Clinical Focus on Primary Immune Deficiencies vol. 1(3) [online], [retrieved on Dec. 22, 2005]. Retrieved from the internet <URL: www.primaryimmune.org/pubs/clinic—focus/cf—dec98.pdf>.
Hassan, M.S. Biological half-life of normal and truncated human IgG3 in scid mice. European Journal of Immunology vol. 21(5) (May 1991), pp. 1319-1322.
Galea et al., “Identification of a biological marker of resistance to AIDS progression”, Cellular Pharmacology AIDS Science, vol. 3, pp. 311-316, 1996.
Scharf et al., “Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Protent than Other Subclasses in Neutralizing HIV Type 1”, Journal of Virology, pp. 6558-6565, Jul. 2001.
Kunert et al., “Stable Recombinant Expression of the Anti HIV-1 Monoclonal Antibody 2F5 After IgG3/IgG1 Subclass Switch in CHO Cells”, Biotechnology and Bioengineering, vol. 67, No. 1, pp. 97-103, Jan. 5, 2000.
Raux et al., “IgG Subclass Distribution in Serum and Various Mucosal Fluids of HIV Type 1—Infected Subjects”, Aids Research and Human Retroviruses, vol. 16, No. 6, pp. 583-594, Nov. 6, 2000.
Haslin et al., “Anti-R7V antibodies as therapeutics for HIV-infected patients in failure of HAART”, Pharmaceutical Biotechnology, vol. 13, pp. 621-624, 2002.
Rubinstein et al., “Preliminary Results of V3 Loop Peptide-Primary Neutralizing Domain Conjugate Phase 1 Vaccine Trial”, Aids Research and Human Retroviruses, vol. 10, Supp. 2, pp. S149-S153, 1994.
Cavacini et al., “Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody”, Journal Of Immunology, vol. 155, No. 7, p. 3638, 1995.
P. Galea, C. Le Contel, J.C. Chermann, “A Novel Epitope R7V Common To All HIV-1 Isolates Is Recognized By Neutralizing IgG Found In HIV-Infected Patients And Immunized Rabbits”, Vaccine 17 (1999) 1454-1461.

Affiliated with

Also associated with

Rating

Immunoglobulin IgG3 as a marker for protecting against... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoglobulin IgG3 as a marker for protecting against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin IgG3 as a marker for protecting against... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3892255